会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Cyclic hexapeptides, their production and use
    • 循环六肽,其生产和使用
    • US5948754A
    • 1999-09-07
    • US739810
    • 1996-10-30
    • Mitsuhiro WakimasuTakashi KikuchiAkira Kawada
    • Mitsuhiro WakimasuTakashi KikuchiAkira Kawada
    • A61K38/00C07K14/575A61K38/12C07K7/64
    • C07K14/57536A61K38/00
    • A cyclic hexapeptide represented by the formula:cyclo�A--Asp(R.sup.1)--Y--NH--CHR.sup.2 --CO--C--D--Trp(N.sup.in --R.sup.3)--! (I)wherein A is a D-acidic-.alpha.-amino acid residue; Y is an acidic-.alpha.-amino acid residue; C is an L-.alpha.-amino acid residue; R.sup.1 is a group represented by the formula: ##STR1## wherein X.sup.1 and X.sup.2 are independently H, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or nitro, and may bind together to form a ring in cooperation with the adjacent carbon atom; R.sup.2 is C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-C.sub.1-3 alkyl, C.sub.1-6 alkylthio-C.sub.1-3 alkyl, C.sub.3-7 cycloalkylthio-C.sub.1-3 alkyl, C.sub.1-5 alkoxy-C.sub.1-3 alkyl, C.sub.3-7 cycloalkoxy-C.sub.1-3 alkyl, C.sub.1-6 alkylthio, C.sub.3-7 cycloalkylthio, C.sub.1-5 alkoxy or C.sub.3-7 cycloalkoxy; R.sup.3 is H, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, --COR.sup.4, --COOR.sup.5 or --CONHR.sup.6 ; when X.sup.1, X.sup.2 and R.sup.3 are all hydrogen atoms, R.sup.2 is not an isobutyl group, or a salt thereof, which exhibits excellent antagonistic action against endothelin receptors, particularly endothelin B receptors.
    • 由式:环[A-Asp(R1)-Y-NH-CHR2-CO-CD-Trp(Nin-R3) - ](I)表示的环状六肽其中A是D-酸性α-氨基酸 残留物 Y是酸性α-氨基酸残基; C是L-α-氨基酸残基; R1是由下式表示的基团:其中X1和X2独立地是H,C1-6烷基,C1-6烷氧基,卤素或硝基,并且可以与相邻的碳原子一起结合形成环; R 2是C 1-6烷基,C 3-7环烷基,C 3-7环烷基-C 1-3烷基,C 1-6烷硫基-C 1-3烷基,C 3-7环烷硫基-C 1-3烷基,C 1-5烷氧基-C 1-3 烷基,C 3-7环烷氧基-C 1-3烷基,C 1-6烷硫基,C 3-7环烷硫基,C 1-5烷氧基或C 3-7环烷氧基; R3是H,C1-6烷基,C3-7环烷基,-COR4,-COOR5或-CONHR6; 当X1,X2和R3都是氢原子时,R2不是对内皮素受体,特别是内皮素B受体具有优异拮抗作用的异丁基或其盐。
    • 4. 发明授权
    • Method for controlling conformation of cyclopentapeptide
    • 控制环戊肽构象的方法
    • US06346604B1
    • 2002-02-12
    • US08969007
    • 1997-11-12
    • Mitsuhiro WakimasuHiroshi InookaSatoshi EndoTakashi Kikuchi
    • Mitsuhiro WakimasuHiroshi InookaSatoshi EndoTakashi Kikuchi
    • C07K102
    • C07K7/64A61K38/00
    • Cyclic pentapeptides having a &ggr;-turn and a &bgr;-turn wherein the cyclic pentapeptide has the following formula (I): Cyclo(—A1—A2—A3—A4—A5—)  (I) wherein A1, A2, A3, A4 and A5 are amino acid residues; said pentapeptide having amino acid residues in positions 1-2-3 to form a &ggr;-turn, and amino acid residues in positions 3-4-5-1 to form a &bgr;-turn in combination with the &ggr;-turn; in which D-&agr;-amino acid residues are selected for A1, A3 and A5 and L-&agr;-amino acid residues are selected for A2 and A4 or wherein L-&agr;-amino acid residues are selected for A1, A3 and A5 and D-&agr;-amino acid residues are selected for A2 and A4; are provided. Compounds having &ggr;-turns and &bgr;-turns can be systhesized, regardless of the kinds of amino acid residues, and it is possible to synthesize compounds in which desired amino acid residues are introduced into sites of &bgr;-turn and &ggr;-turn based on their importance from the viewpoint of biological activity. The present invention is therefore available for design of compounds having biological activity.
    • 具有γ-匝和β-匝的环状五肽,其中环状五肽具有下式(I):其中A1,A2,A3,A4和A5是氨基酸残基;所述五肽在1-2位具有氨基酸残基 -3以形成γ-匝数,以及位置3-4-5-1处的氨基酸残基与γ匝组合形成β-匝数;其中选择D-α-氨基酸残基用于A1, A2和A4选择A3和A5和L-α-氨基酸残基,或选择A1,A3和A5的L-α-氨基酸残基,A2和A4选择D-α-氨基酸残基; 具有γ-匝数和β-匝数的化合物可以被控制,而不管氨基酸残基的种类如何,并且可以合成将期望的氨基酸残基引入β-匝和γ-匝的位点的化合物 基于它们从生物活性的角度的重要性。 因此,本发明可用于设计具有生物活性的化合物。
    • 5. 发明授权
    • Endothelin analogs and uses thereof
    • 内皮素类似物及其用途
    • US5352659A
    • 1994-10-04
    • US837780
    • 1992-02-14
    • Mitsuhiro WakimasuTakashi KikuchiKazuki Kubo
    • Mitsuhiro WakimasuTakashi KikuchiKazuki Kubo
    • A61K38/00C07K14/575A61K37/02C07K7/10
    • C07K14/57536A61K38/00
    • Disclosed are a peptide represented by formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein M represents a mercaptoacyl group; P, Q, R, S, T, U, V, W, X, Y and Z each represent amino acid residues, wherein an amino acid side chain of Y is either a substituted saturated aliphatic hydrocarbon group having 1 to 15 carbon atoms or an unsubstituted saturated aliphatic hydrocarbon group having 4 to 15 carbon atoms other than (1S)-1-methylpropyl; (2) a method for producing the above-mentioned peptide or the salt thereof, which comprises subjecting a peptide represented by formula (II) or a salt thereof to an oxidation reaction:M-P-Cys-Q-R-S-T-Asp-U-Glu-Cys-Val-Tyr-V-Cys-His-W-X-Y-Ile-Z-OH(II)wherein M, P, Q, R, S, T, U, V, W, X, Y and Z are as diefined above; and (3) use of the above-mentioned peptide or the pharmaceutically acceptable salt thereof as an anti-endothelin agent.
    • 公开了由式(I)表示的肽或其药学上可接受的盐:巯基酰基; P,Q,R,S,T,U,V,W,X,Y和Z各自表示氨基酸残基,其中Y的氨基酸侧链是具有1至15个碳原子的取代的饱和脂族烃基或 除(1S)-1-甲基丙基以外具有4〜15个碳原子的未取代的饱和脂肪族烃基; (2)上述肽或其盐的制造方法,其特征在于,将由式(II)表示的肽或其盐进行氧化反应:MP-Cys-QRST-Asp-U-Glu-Cys 其中M,P,Q,R,S,T,U,V,W,X,Y和Z的Val-Tyr-V-Cys-His-WXY-Ile-Z-OH(II) 和(3)使用上述肽或其药学上可接受的盐作为抗内皮素剂。
    • 6. 发明授权
    • Peptide derivatives having vasodilating activity
    • 具有血管扩张活性的肽衍生物
    • US5306808A
    • 1994-04-26
    • US768269
    • 1991-10-17
    • Mitsuhiro WakimasuTakashi KikuchiKazuki Kubo
    • Mitsuhiro WakimasuTakashi KikuchiKazuki Kubo
    • A61K38/00C07K14/575C07K7/10
    • C07K14/57536A61K38/00
    • Disclosed are a peptide derivative represented by the formula [I] or a pharmaceutically acceptable salt thereof: ##STR1## wherein A, B, C, D, E and F each represent amino acid residues, and satisfy any one condition of (i) A=Ser, B=Ser, C=Ser, D=Leu, E=Met and F=Phe, (ii) A=Ser, B=Ser, C=Ser, D=Trp, E=Leu and F=Phe, and (iii) A=Thr, B=Phe, C=Thr, D=Tyr, E=Lys and F=Tyr; and W, X, Y and Z each represent amino acid residues, and satisfy any one condition of (i) at least one of W and Y is an amino acid residue other than an L-alanine residue or other than an L-cysteine residue, (ii) X is an amino acid residue other than an L-Lysine residue, and (iii) Z is an amino acid residue other than an L-aspartic acid residue; (2) a method for producing the peptide derivative or the salt thereof; and (3) an agent for improving a circulatory function mainly comprising the peptide derivative or the salt thereof, such as a vasodilator or a vasoconstrictor.
    • PCT No.PCT / JP91 / 00165 Sec。 371日期1991年10月17日 102(e)日期1991年10月17日PCT 1991年2月12日提交PCT公布。 出版物WO91 / 13089 1991年9月5日公开。公开是由式(I)表示的肽衍生物或其药学上可接受的盐:(*化学结构*)-Ile-Ile-Trp-OH其中A,B,C,D,E (i)A = Ser,B = Ser,C = Ser,D = Leu,E = Met和F = Phe的任何一个条件,(ii)A = Ser,B = Ser,C = Ser,D = Trp,E = Leu和F = Phe,和(iii)A = Thr,B = Phe,C = Thr,D = Tyr,E = Lys和F = Tyr; 并且W,X,Y和Z各自表示氨基酸残基,并且满足(i)W和Y中的至少一个是L-丙氨酸残基以外的氨基酸残基或L-半胱氨酸残基以外的任一条件 ,(ii)X是除L-赖氨酸残基以外的氨基酸残基,(iii)Z是除了L-天冬氨酸残基以外的氨基酸残基; (2)生成肽衍生物或其盐的方法; 和(3)主要由肽衍生物或其盐例如血管扩张剂或血管收缩剂改善循环功能的药剂。
    • 7. 发明授权
    • Pentapeptide with specific conformation, its production and use
    • 具有特定构象的五肽,其生产和使用
    • US06610655B2
    • 2003-08-26
    • US09999432
    • 2001-11-15
    • Mitsuhiro WakimasuHiroshi InookaSatoshi EndoTakashi Kikuchi
    • Mitsuhiro WakimasuHiroshi InookaSatoshi EndoTakashi Kikuchi
    • C07K102
    • C07K7/64A61K38/00
    • Cyclic pentapeptides are disclosed having the following formula (I)-Cyclo(-A1-A2-A3-A4-A5-)-wherein A1, A2, A3, A4 and A5 are amino acid residues. The pentapeptide has amino acid residues in positions 1-2-3 to form a &ggr;-turn, and amino acid residues in positions 3-4-5-1 to form a &bgr;-turn in combination with the &ggr;-turn. D-&agr;-amino acid residues are selected for A1, A3, and A5 and L-&agr;-amino acid residues are selected for A2 and A4. Compounds having &ggr;-turns and &bgr;-turns can be synthesized, regardless of the kinds of amino acid residues, and it is possible to synthesize compounds in which desired amino acid residues are introduced into sites of &bgr;-turn and &ggr;-turn based on their importance from the viewpoint of biological activity. The present invention is therefore available for design of compounds having biological activity.
    • 公开了具有下式(I)-Cyclo(-A1-A2-A3-A4-A5-))的环五肽 - 其中A1,A2,A3,A4和A5是氨基酸残基。 五肽在1-2-3位具有氨基酸残基以形成γ-转角,并且3-4-5-1位置的氨基酸残基与γ转弯结合形成β-转角。 选择A1,A3和A5的D-α-氨基酸残基,A2和A4选择L-α-氨基酸残基。 可以合成具有γ-匝数和β-匝数的化合物,而不考虑氨基酸残基的种类,并且可以合成其中所需氨基酸残基被引入β-匝和γ-匝转位点的化合物 从生物活动的角度来看重要。 因此,本发明可用于设计具有生物活性的化合物。
    • 8. 发明授权
    • Pentapeptide with specific conformation, its production and use
    • 具有特定构象的五肽,其生产和使用
    • US5965526A
    • 1999-10-12
    • US551251
    • 1995-10-31
    • Mitsuhiro WakimasuHiroshi InookaSatoshi EndoTakashi Kikuchi
    • Mitsuhiro WakimasuHiroshi InookaSatoshi EndoTakashi Kikuchi
    • A61K38/00C07K1/00C07K7/64A61K38/12
    • C07K7/64C07K1/00A61K38/00
    • Cyclic pentapeptides are disclosed having the following formula (I) --Cyclo(-A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 -A.sub.5 -)-- wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4 and A.sub.5, are amino acid residues. The pentapeptide has amino acid residues in positions 1-2-3 to form a .gamma.-turn, and amino acid residues in positions 3-4-5-1 to form a .beta.-turn in combination with the .gamma.-turn. D-.alpha.-amino acid residues are selected for A.sub.1, A.sub.3, and A.sub.5 and L-.alpha.-amino acid residues are selected for A.sub.2 and A.sub.4. Compounds having .gamma.-turns and .beta.-turns can be synthesized, regardless of the kinds of amino acid residues, and it is possible to synthesize compounds in which desired amino acid residues are introduced into sites of .beta.-turn and .gamma.-turn based on their importance from the viewpoint of biological activity. The present invention is therefore available for design of compounds having biological activity.
    • 公开了具有下式(I)-Cyclo(-A1-A2-A3-A4-A5-))的环五肽,其中A1,A2,A3,A4和A5是氨基酸残基。 五肽在1-2-3位具有氨基酸残基以形成γ转角,并且3-4-5-1位置的氨基酸残基与γ转角组合形成β转角。 A1,A3和A5选择D-α-氨基酸残基,A2和A4选择L-氨基酸残基。 可以合成具有γ-转角和β-转角的化合物,而不管氨基酸残基的种类如何,并且可以合成其中所需氨基酸残基被引入β-转角和γ转角的位点的化合物,基于它们 从生物活动的角度来看重要。 因此,本发明可用于设计具有生物活性的化合物。